Online citations, reference lists, and bibliographies.
← Back to Search

Breast Cancer Molecular Subtypes In Patients With Locally Advanced Disease: Impact On Prognosis, Patterns Of Recurrence, And Response To Therapy.

K. Huber, L. Carey, D. Wazer
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Gene expression profiling has led to the discovery of 4 distinct molecular subtypes of breast cancer: luminal A, luminal B, basal like, and HER2 enriched. Investigation of these subtypes in women with breast cancer has given insight into the heterogeneous biology and outcomes in patients with locally advanced disease. These subtypes have been found to be predictors for survival, response to systemic therapy, and locoregional recurrence. This review discusses the biology of locally advanced breast cancer and the available data on how molecular subtype may provide information regarding response to treatment and prognosis of women with locally advanced breast cancer.
This paper references
10.1073/pnas.1732912100
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
C. Sotiriou (2003)
10.1007/s10549-008-0086-2
Pattern of metastatic spread in triple-negative breast cancer
R. Dent (2008)
10.1056/NEJMOA052306
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
M. Piccart-Gebhart (2005)
10.1007/s10549-008-0102-6
Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status
W. Foulkes (2008)
10.1093/ANNONC/MDM509
Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.
M. Colleoni (2008)
10.1007/978-1-4757-3656-4
AJCC Cancer Staging Manual
M. B. Amin (2002)
10.1158/0008-5472.CAN-04-4115
Gene expression profiling identifies molecular subtypes of inflammatory breast cancer.
F. Bertucci (2005)
10.1200/JCO.2007.14.5565
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
M. Kyndi (2008)
10.1002/cncr.22981
Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy
N. Goldstein (2007)
10.1073/pnas.191367098
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
10.1200/JCO.2006.07.0250
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
Z. Gabos (2006)
10.1054/bjoc.1999.0930
Screen-detected breast cancers have a lower mitotic activity index
R. P. Groenendijk (2000)
10.3816/CBC.2008.n.028
Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer.
S. Crabb (2008)
10.1001/JAMA.295.21.2492
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
L. Carey (2006)
10.1002/cncr.23930
Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer
N. Lin (2008)
10.1200/JCO.1998.16.8.2672
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B. Fisher (1998)
10.1158/1078-0432.CCR-04-2421
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
R. Rouzier (2005)
10.1016/J.BREAST.2007.02.006
The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial.
A. Rody (2007)
10.1002/(SICI)1097-0142(19980615)82:12<2366::AID-CNCR10>3.0.CO;2-N
Inflammatory breast carcinoma incidence and survival
S. Chang (1998)
10.1158/0008-5472.CAN-07-5644
Subtypes of breast cancer show preferential site of relapse.
M. Smid (2008)
10.1007/s10549-005-9015-9
Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling
S. V. Laere (2005)
10.1016/J.EJCA.2004.08.021
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
T. Sørlie (2004)
10.1200/JCO.2007.14.4287
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
P. Nguyen (2008)
10.1002/cncr.22618
Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype
K. Bauer (2007)
10.1016/J.IJROBP.2004.02.018
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
T. Buchholz (2004)
10.1200/JCO.2005.02.6914
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
V. Guarneri (2006)
10.1158/1078-0432.CCR-04-0220
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
T. Nielsen (2004)
10.1007/S12094-008-0265-Y
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
A. Sánchez-muñoz (2008)
Sensitization of breast cancer cells to radiation by trastuzumab.
Ke Liang (2003)
10.1200/JCO.2008.18.1370
Supervised risk predictor of breast cancer based on intrinsic subtypes.
J. Parker (2009)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
10.1200/JCO.2005.02.0818
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
L. Gianni (2005)
10.1158/1078-0432.CCR-06-3045
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
R. Dent (2007)
10.1073/pnas.0932692100
Repeated observation of breast tumor subtypes in independent gene expression data sets
T. Sørlie (2003)
10.1200/JCO.2007.14.4147
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
C. Liedtke (2008)
10.1200/JCO.1983.1.4.227
Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.
B. Fisher (1983)
10.1158/1078-0432.CCR-06-1109
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
L. Carey (2007)
10.1148/RADIOLOGY.199.3.8638010
Screening interval breast cancers: mammographic features and prognosis factors.
H. Burrell (1996)
10.1093/JNCI/91.23.2020
Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers.
P. Porter (1999)
10.1200/JCO.2006.06.5664
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
B. Haffty (2006)
10.1007/s10549-007-9632-6
Epidemiology of basal-like breast cancer
Robert C. Millikan (2007)
Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
R. Pietras (1999)
10.1056/NEJMOA052122
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
10.1186/bcr1672
Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women
A. Jemal (2007)
10.1093/JNCI/DJI172
Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.
K. Hance (2005)
10.1158/1078-0432.CCR-07-5003
Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening
H. Sihto (2008)
10.1056/NEJMOA052933
Concordance among gene-expression-based predictors for breast cancer.
C. Fan (2006)
10.1200/JCO.1999.17.2.460
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
H. Kuerer (1999)
10.1002/IJC.2910430205
Structure and expression of c‐erbB‐2 and EGF receptor genes in inflammatory and non‐inflammatory breast cancer: Prognostic significance
M. Gue′rin (1989)
10.1111/j.1365-2559.1991.tb00229.x
pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up
C. Elston (1991)
10.1002/1097-0142(19800115)45:2<349::AID-CNCR2820450226>3.0.CO;2-P
Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer
E. Fisher (1980)
10.3816/CBC.2007.N.012
Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status.
L. Fernández-Morales (2007)
10.1186/bcr755
WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer
C. Kleer (2003)
10.1093/jnci/djn389
Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control
A. Jemal (2008)



This paper is referenced by
10.1016/j.acra.2018.01.023
Breast Cancer Molecular Subtype Prediction by Mammographic Radiomic Features.
W. Ma (2019)
10.1007/s11307-019-01383-w
Radiomic Signatures Derived from Diffusion-Weighted Imaging for the Assessment of Breast Cancer Receptor Status and Molecular Subtypes
D. Leithner (2019)
10.1186/s13058-019-1187-z
Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results
D. Leithner (2019)
10.1016/j.jconrel.2014.06.010
Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers.
K. Nagano (2014)
10.1007/s12094-010-0538-0
Breast cancer, neoadjuvant chemotherapy and residual disease
M. Chávez-MacGregor (2010)
10.1016/j.febslet.2014.02.007
PML tumour suppression and beyond: Therapeutic implications
C. Gamell (2014)
10.2217/pgs.11.10
DNA amplification techniques in pharmacogenomics.
Jean-Étienne R L Morlighem (2011)
10.1016/J.CIRESP.2011.09.004
Propuesta de una nueva estrategia terapéutica multidisciplinar en la mujer con cáncer de mama y afectación del ganglio centinela
Benigno Acea (2012)
10.1007/s10147-014-0727-x
Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice
J. Gavilá (2014)
10.3390/cancers12082024
Non-Invasive Assessment of Hypoxia and Neovascularization with MRI for Identification of Aggressive Breast Cancer
B. Bennani-Baiti (2020)
10.1158/1078-0432.CCR-18-2782
Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database
Ki-Tae Hwang (2018)
10.3332/ecancer.2017.715
Bone metastasis risk factors in breast cancer
C. Pulido (2017)
Análisis de sobrevida según perfil biológico de pacientes uruguayas con cáncer de mama
C. Castillo (2012)
Molecular subtypes in patients with inflammatory breast cancer; a single center experience.
N. Kertmen (2015)
10.1016/j.acra.2016.11.012
Association Between Imaging Characteristics and Different Molecular Subtypes of Breast Cancer.
Ming-xiang Wu (2017)
10.1038/npjbcancer.2016.12
Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set
H. Li (2016)
10.1067/j.cpradiol.2018.08.003
Relationships Between Human-Extracted MRI Tumor Phenotypes of Breast Cancer and Clinical Prognostic Indicators Including Receptor Status and Molecular Subtype.
J. Net (2018)
10.1007/s11307-018-1298-4
Development of a Non-invasive Assessment of Hypoxia and Neovascularization with Magnetic Resonance Imaging in Benign and Malignant Breast Tumors: Initial Results
A. Stadlbauer (2018)
10.3389/fonc.2013.00174
Is PML a Tumor Suppressor?
M. Mazza (2013)
10.1016/j.breast.2016.12.007
Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer-specific survival.
I. Kindts (2017)
10.1007/s10549-011-1532-0
Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today?
B. Gerber (2011)
10.1002/jmri.24879
Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms
L. Grimm (2015)
10.1016/j.ophtha.2010.12.011
Genetic variants in pigment epithelium-derived factor influence response of polypoidal choroidal vasculopathy to photodynamic therapy.
I. Nakata (2011)
10.1007/978-0-85729-991-8_11
Follow-Up in Inflammatory Breast Cancer
Flavia Morales-Vásquez (2013)
10.1016/j.breast.2018.02.028
Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.
A. Baumgartner (2018)
10.1093/annonc/mdt082.9
37PBRAIN METASTASES IN TRIPLE RECEPTOR-NEGATIVE BREAST CANCER: FREQUENCY, RISK GROUPS AND PROGNOSIS
H. Tawfik (2013)
10.3348/kjr.2016.17.6.846
Is There a Correlation between the Presence of a Spiculated Mass on Mammogram and Luminal A Subtype Breast Cancer?
Song Liu (2016)
10.7314/APJCP.2012.13.5.1881
Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002- 2011.
Maryam Kadivar (2012)
10.1248/bpb.b17-01041
Development and Evaluation of Antibody Proteomics Technology for Rapid and Comprehensive Identification of Potential Biomarkers and Therapeutic Targets.
K. Nagano (2018)
10.1530/ERC-11-0102
Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival.
Q. Zheng (2011)
10.1007/978-3-319-43504-6_17
Use Case III: Imaging Biomarkers in Breast Tumours. Development and Clinical Integration
Maria Adele Marino (2017)
10.1016/j.acra.2016.11.021
Role of Imaging in the Era of Precision Medicine.
A. Giardino (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar